60 related articles for article (PubMed ID: 344104)
21. Proceedings: Local Corynebacterium parvum therapy in early breast cancer.
Ackroyd NW; Boak JL
Br J Surg; 1976 Aug; 63(8):659. PubMed ID: 953485
[No Abstract] [Full Text] [Related]
22. Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen.
Orlando L; Colleoni M; Curigliano G; Nolè F; Ferretti G; Masci G; Peruzzotti G; Minchella I; Intra M; Veronesi P; Viale G; Goldhirsch A
Anticancer Res; 2001; 21(6A):4135-9. PubMed ID: 11911307
[TBL] [Abstract][Full Text] [Related]
23. Toxic and immunologic side effects of daily C. parvum-infusion in treatment-resistant cancer patients.
Mayr AC; Westerhausen M; Senn HJ
Dev Biol Stand; 1977 Apr 13-15; 38():523-7. PubMed ID: 608546
[TBL] [Abstract][Full Text] [Related]
24. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival.
Cance WG; Carey LA; Calvo BF; Sartor C; Sawyer L; Moore DT; Rosenman J; Ollila DW; Graham M
Ann Surg; 2002 Sep; 236(3):295-302; discussion 302-3. PubMed ID: 12192316
[TBL] [Abstract][Full Text] [Related]
26. Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma.
Karakousis CP; Didolkar MS; Lopez R; Baffi R; Moore R; Holyoke ED
Cancer Treat Rep; 1979; 63(11-12):1739-43. PubMed ID: 393377
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
[TBL] [Abstract][Full Text] [Related]
28. NTP Toxicology and Carcinogenesis Studies of Oxazepam (CAS No. 604-75-1) in Swiss-Webster and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Aug; 443():1-321. PubMed ID: 12595920
[TBL] [Abstract][Full Text] [Related]
29. Monitoring of a multi-modal schedule for the treatment of disseminated breast cancer.
McIntosh IH; Bejrajati P; Goodfellow T; Palmer BV; Greening WP
Dev Biol Stand; 1977 Apr 13-15; 38():471-6. PubMed ID: 344101
[TBL] [Abstract][Full Text] [Related]
30. Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum.
Lichtenstein A; Berek J; Bast R; Spina C; Hacker N; Knapp RC; Zighelboim J
J Biol Response Mod; 1984 Aug; 3(4):371-8. PubMed ID: 6541243
[TBL] [Abstract][Full Text] [Related]
31. Immunological response in patients receiving Corynebacterium parvum therapy.
Osborn DE; Castro JE
Clin Oncol; 1977 Jun; 3(2):155-64. PubMed ID: 872468
[No Abstract] [Full Text] [Related]
32. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies.
Dritschilo A; Huang CH; Rudin CM; Marshall J; Collins B; Dul JL; Zhang C; Kumar D; Gokhale PC; Ahmad A; Ahmad I; Sherman JW; Kasid UN
Clin Cancer Res; 2006 Feb; 12(4):1251-9. PubMed ID: 16489081
[TBL] [Abstract][Full Text] [Related]
33. Effects of dose and schedule of immune stimulant on efficacy of combination Corynebacterium parvum-cyclophosphamide treatment for a murine mammary adenocarcinoma.
Purnell DM; Bartlett GL; Kreider JW
Cancer Res; 1979 Jan; 39(1):1-5. PubMed ID: 761179
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy of an established rat mammary adenocarcinoma (13762A) with intratumor injection of Corynebacterium parvum.
Kreider JW; Bartlett GL; Purnell DM; Webb S
Cancer Res; 1978 Mar; 38(3):689-92. PubMed ID: 626972
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of thermal response of normal and malignant tissues by Corynebacterium parvum.
Urano M; Yamashita T; Suit HD; Gerweck LE
Cancer Res; 1984 Jun; 44(6):2341-7. PubMed ID: 6722772
[TBL] [Abstract][Full Text] [Related]
36. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
37. Making use of the primary tumour.
Baars A; Buter J; Pinedo HM
Bioessays; 2003 Jan; 25(1):79-86. PubMed ID: 12508286
[TBL] [Abstract][Full Text] [Related]
38. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].
Bustová I
Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435
[TBL] [Abstract][Full Text] [Related]
39. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
Klaassen DJ; Rapp EF; Hirte WE
Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
[TBL] [Abstract][Full Text] [Related]
40. C. parvum immuntherapy of transplanted rat tumours.
Pimm MV; Baldwin RW
Int J Cancer; 1977 Dec; 20(6):923-32. PubMed ID: 591131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
